Alnylam (2014). Alnylam and Genzyme form transformational alliance for RNAi therapeutics as genetic medicines. Available at http://investors.alnylam.com/releasedetail.cfm?ReleaseID=818735 (accessed February3, 2014).
2.
BartunekJ., BehfarA., DolatabadiD., et al. (2013). Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J. Am. Coll. Cardiol., 61, 2329–2338.
3.
Biogen Idec and Sangamo (2014). Biogen Idec and Sangamo BioSciences announce global collaboration to develop treatments for hemoglobinopathies. Available at www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2276&M=NewsV2&PID=61997 (accessed February3, 2014).
4.
Cardio3 BioSciences (2014). Cardio3 BioSciences receives IND clearance from the FDA for its CHART-2 phase III heart failure clinical trial. Available at www.c3bs.com/sites/default/files/press/cardio3_biosciences_receives_fda_authorization.pdf (accessed February5, 2014).
5.
Celladon (2014). Celladon announces pricing of initial public offering. Available at http://ir.celladon.net/releasedetail.cfm?ReleaseID=821990 (accessed February5, 2014).
6.
Imperial College London (2014a). Gene therapy for inherited blindness produces promising first results. Available at www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_16-1-2014-12-31-33 (accessed February6, 2014).
7.
Imperial College London (2014b). Gene therapy for Parkinson's disease yields promising results in first patients. Available at www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_9-1-2014-16-19-43 (accessed February6, 2014).
8.
MacLarenR.E., GroppeM., BarnardA.R., et al. (2014). Retinal gene therapy inpatients with choroideremia: initial findings from a phase 1/2 clinical trial. Available at www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2962117-0/fulltext (accessed February6, 2014).
9.
Oxford University and Syncona (2014). Oxford University and Syncona announce the formation of Nightstar, a company developing retinal gene therapies. Available at www.biospace.com/news_story.aspx?StoryID=322531 (accessed February6, 2014).
10.
PalfiS., GurruchagaJ.M., RalphG.S., et al. (2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Available at www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961939-X/fulltext (accessed February6, 2014).
11.
uniQure (2014). uniQure announces pricing of initial public offering. Available at www.uniqure.com/news/186/182/uniQure-Announces-Pricing-of-Initial-Public-Offering.html (accessed February5, 2014).
